Kamp: Supreme Court decision in "pay for delay" case could harm pharma

04/2/2013

Coalition for Healthcare Communication Executive Director John Kamp said in a commentary posted Monday on the Coalition's Website that if the forthcoming decision by the U.S. Supreme Court in FTC v. Actavis regarding AndroGel is decided against the pharmaceuticals industry, it "could create a significant bottom line hit to our business. A decision against pharma would further shorten the patent protection period on many branded drugs." Kamp provided a summary of the important issues at stake in the case, for which oral arguments were heard on March 25. Despite the legal challenges, "don't count the industry out yet," Kamp said. Read more.

View Full Article in:

http://www.cohealthcom.org/2013/04/01/kamp-commentary-supreme-court-decision-cou...

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR